公司資料
Harmony Biosciences 股價、新聞與催化劑
- 股票代碼:
- HRMY
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
38.14 USD (+0.05%)
收盤價
最後更新: 2026年8月17日
1.79B USD
市值
股價為何變動
As of Aug 17, 2026, HRMY was little changed and closed at $38.14. No new same-company headline was identified in the current news window.
公司概覽
Sleep and Neurologic Disorders
Harmony Biosciences develops and commercializes medicines for rare neurologic diseases. Its business is anchored by therapies that regulate wakefulness and sleep-wake signaling.
WAKIX Franchise
WAKIX, or pitolisant, is a histamine H3 receptor antagonist/inverse agonist used in narcolepsy and is the company's principal commercial product.
Pitolisant Lifecycle Programs
Harmony is extending pitolisant through a gastro-resistant formulation, a higher-dose program and a newly acquired amorphous form intended to support additional central-nervous-system indications.
Orexin-2 Program
BP-205 is an orexin-2 receptor agonist in Phase 1 development and is intended to complement Harmony's existing wake-promoting franchise with a distinct mechanism.
未來催化劑
- NDA submission for a gastro-resistant formulation of pitolisant in the second quarter of 2026.
- Phase 1 pharmacokinetic data for BP-205 around mid-2026.
- Phase 3 data for high-dose pitolisant in 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。